If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
107
results.
Updated on
05/09/2025 [06:58:00]
Absstract of: US2025279181A1
Techniques for detection of occurrence of a meal are provided. In some embodiments, the techniques may involve obtaining a plurality of glucose measurements indicative of a glucose level in a body of a patient during an analysis interval. The techniques may further involve detecting an occurrence of a meal during the analysis interval based on the plurality of glucose measurements obtained during the analysis interval. The techniques may further involve updating a user interface to include an indication of the meal detected during the analysis interval.
Absstract of: AU2025220713A1
Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time. Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time. ug y s t e m s , m e t h o d s , a n d d e v i c e s p r o v i d e a l a r m s a n d a l e r t s i n a n o n - b o d y n e t w o r k e d u g
Absstract of: US2025276127A1
The present invention relates to a novel medical use of glucagon, and other compounds with glucagon activity, as vasodilators, to assist in the delivery of therapeutic agents or in the operation of sensor devices which determine the level of analytes in the blood. In particular, the compound is administered in temporal coordination with the active agent and/or in conjunction with determination of the analyte by a bodily sensor, and at a site which is in the vicinity of the site of administration of the active agent and/or of the site(s) of sensing of the analyte by the bodily sensor. This includes in particular the delivery of insulin in the treatment of diabetes, and the determination of blood glucose levels by glucose sensors. Also provided herein are integrated systems for performing the medical uses and therapies.
Absstract of: US2025275721A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: US2025275722A1
Wearable electronic devices can be equipped with sensors to measure heart rate, blood oxygen level, respiratory rate, blood pressure, blood sugar level, and skin temperature. The device can include graphene-based sensors to measure heart rate, blood oxygen level, respiratory rate, blood pressure, blood sugar level, and skin temperature. The device may include a process for judging the reliability of biological sensor measurements using a capacitance measurement. The capacitance measurement can be conducted on the device and can determine the quality of contact between the device and the wearer. The device can display warnings to the wearer when the quality of contact between the device and its wearer is not sufficient to conduct a reliable biological sensor measurement.
Absstract of: US2025275695A1
A method of manufacturing a metabolic sensor includes assembling a working wire for a metabolic sensor and exposing the interference layer to an oxidizing agent. The exposing is performed prior to sterilizing the working wire. The assembling comprises forming an interference layer on a substrate, the substrate having an electrically conductive surface; forming an enzyme layer on the interference layer, and forming a glucose limiting layer on the enzyme layer.
Absstract of: BG113859A
The obstetric device contains a power supply battery module, a sensor unit, a minicomputer configuration (10 - server) and a transmitter of sensor information in digital form (9). The sensor unit includes in combination sensor elements for: pressure (1), sensing uterine activity through contractions and fetal motor activity; an ultrasound minigenerator and radiation receiver (2), using the Doppler effect when reflecting the signal from the contracting fetal heart muscle; an electronic sphygmomanometer or photoplethysmograph (6) for monitoring the mother's blood pressure; a reflex pulse oximeter for highly accurate determination of blood saturation and heart rate (pulse) of the mother (5, 7); a photo-acoustic spectrometer (8 - acoustic detector) for measuring the glucose level in the blood of the pregnant woman. The received sensory information from all non-electrical transducers is digitized and translated through an application on a local server (9 - smartphone) to a server (10) of a clinic or a treating gynecologist.
Absstract of: WO2025175641A1
An active Fano resonance blood glucose sensor, relating to the field of non-invasive blood glucose monitoring. The blood glucose sensor comprises a resonator, an excitation layer, a low-noise amplifier (8) and a phase shifter (9), wherein the resonator, the low-noise amplifier (8) and the phase shifter (9) form a connection loop; the resonator is provided on the excitation layer; and the excitation layer is connected to an external excitation source. By using the phase shifter (9), the phase of an active circuit can be changed to selectively enhance resonance, improve the resonance Q factor, and realize detection of minor changes in blood glucose concentration, and thus the active Fano resonance blood glucose sensor can be applied to human blood glucose sensing and the problems in the prior art of poor stability and robustness. Moreover, by using the resonator and the excitation layer, self-reference error elimination can be achieved, significantly improving the performance of the microwave blood glucose sensor and improving the reliability of blood glucose measurement.
Absstract of: US2025272940A1
Modulation-encoded light, using different spectral bin coded light components, can illuminate a stationary or moving (relative) target object or scene. Response signal processing can use information about the respective different time-varying modulation functions, to decode to recover information about a respective response parameter affected by the target object or scene. Electrical or optical modulation encoding can be used. LED-based spectroscopic analysis of a composition of a target (e.g., SpO2, glucose, etc.) can be performed; such can optionally include decoding of encoded optical modulation functions. Baffles or apertures or optics can be used, such as to constrain light provided by particular LEDs. Coded light illumination can be used with a focal plane array light imager receiving response light for inspecting a moving semiconductor or other target. Encoding can use orthogonal functions, such as an RGB illumination sequence, or a sequence of combinations of spectrally contiguous or non-contiguous colors.
Absstract of: WO2025178832A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Absstract of: WO2025175650A1
The present disclosure relates to the field of noninvasive glucose monitoring, and specifically, to a wearable noninvasive microwave glucometer. According to the present disclosure, an active Fano resonance-based glucose sensor (11) and a glucose monitoring system (12) are integrated, such that the whole noninvasive microwave glucometer features compactness, wearability, and high sensitivity. Moreover, the active Fano resonance-based glucose sensor (11) monitors the blood glucose concentration on the basis of a microwave signal generated by a microwave signal generation-processing unit, and can thus achieve noninvasive, real-time glucose monitoring in a human and hypoglycemia alarm. The arrangement of the active Fano resonance-based glucose sensor (11), a power supply unit (14), the microwave signal generation-processing unit, and a screen (15) can improve the resolution and sensitivity of blood glucose monitoring, thereby meeting the clinical precision requirements.
Absstract of: US2025269113A1
Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.
Absstract of: US2025268491A1
A cover apparatus for obstructing a transdermal glucose monitor from view includes a top wall shaped and a perimeter wall. The perimeter wall is coupled to and extends away from the top wall. The perimeter wall and the top wall define a cavity which is dimensioned and configured to receive the transdermal glucose monitor therein
Absstract of: EP4606303A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Absstract of: US12396664B1
To better understand the impact of glycemic events, some entities have begun examining the relationship between the blood glucose level and another physiological parameter. However, this relationship can be difficult to understand. Introduced here are computer programs and associated computer-implemented techniques for discovering glycemic events in a series of data values representative of blood glucose measurements and then altering the measurement schedule of a sensor capable of generating measurements in a dimension other than blood glucose based on the glycemic events. By altering the measurement schedule of the sensor, a diabetes management platform can better understand how, if at all, dimensions other than blood glucose are related to the glycemic health state of a subject whose blood glucose level is being monitored.
Absstract of: WO2025175025A1
A casing for an insulin delivery system includes a housing, a lid, and a gasket. The housing includes a first overmolded rubber member defining a first channel part. The lid includes a second overmolded rubber member defining a second channel part. The lid is couplable to the housing to define an enclosure and a cavity. The enclosure is configured to receive an insulin pump. The cavity receives the rubber members such that the channel parts define a channel when the lid is removably coupled to the housing. The channel encloses a tubing to fluidly couple the insulin pump to an outside of the casing. The gasket is received between the housing and the lid to seal the housing with the lid, preventing fluid ingress into the cavity and the enclosure and providing a waterproof seal between the cavity and the enclosure when the lid is removably coupled to the housing.
Absstract of: US2025266143A1
Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.
Absstract of: US2025266171A1
A blood glucose prediction method includes training a prediction model; receiving a first data set of an object; when a first data type is a label, updating a personalized database; counting the personalized data records to generate a first total number; if the first total number is greater than or equal to a first threshold value, screening personalized data calibrated records; if the first total number is equal to a second threshold value, training a personalized prediction model; when the first data type is a prediction, counting the personalized data records to generate a second total number; if the second total number is smaller than the second threshold value, based on the prediction model, making a prediction; and if the second total number is equal to the second threshold value, based on the prediction model and the personalized prediction model, making a personalized prediction.
Absstract of: US2025267580A1
A battery-powered infusion pump for medicament delivery (e.g., insulin) may collect and store data related to the pump. The infusion pump can communicate some or all of the stored data to another device and control the timing and amount of data communicated in order to conserve battery life.
Absstract of: US2025262381A1
A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.
Absstract of: US2025262379A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Absstract of: US2025261885A1
Methods, computers, and systems used to improve accuracy of glucose level measurement of an in vivo positioned sensor are disclosed herein. The method includes collecting signal data from an in vivo positioned sensor over a period of time, wherein the signal data is indicative of glucose levels, analyzing the collected signal data and identifying signal data points that occur most frequently within the collected data, correlating the identified signal data points to a normal physiological level for glucose, the identified signal data points being taken from the signal data collected from the in vivo positioned sensor, and deriving glucose levels from the collected signal data using the identified signal data points as a reference point for the normal physiological level of the glucose for a user of the in vivo positioned sensor
Absstract of: US2025261881A1
A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.
Absstract of: GB2638147A
A system 100 comprises a number of devices 102 in communication with one another. The devices 102 are associated with a user 104 and may comprise a smartphone 102A, wearable devices such as a headset 102B or heart rate monitor 102C, and other local devices 102D,102E such as smart speakers including a microphone, cameras, motion sensors or other devices used for monitoring the area around the user 104. The wearable devices may comprise sensors for monitoring physiological parameters or an IMU for monitoring position or movement of the user 104. One or more of the devices 102 can be configured to detect a critical event. A critical event is an event considered to be dangerous or causes the user to require assistance such as cardiac events, a drop in blood sugar level, or a fall. If a critical event occurs, one or more of the devices 102 can raise an alarm or contact assistance. Before such takes place, the system confirms that a prospective critical event is an actual critical event by obtaining additional data from another device 102 in the system. This can help to avoid false alarms or other calls for assistance being raised unnecessarily.
Nº publicación: EP4601730A1 20/08/2025
Applicant:
GOVERNING COUNCIL UNIV TORONTO [CA]
The Governing Council of the University of Toronto
Absstract of: WO2024077402A1
The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa ~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.
BOPI
Electronic site
